Trial
From Kidney Cancer Resource
Overview
Phase I clinical trials, where a drug is tested for safety.
Phase II testing is the midpoint for a drug's development.
If Phase II is successful, then a drug moves on to:
Phase III, the pivotal stage where a product is tested in a large patient population to determine its effectiveness in treating disease
Details
Phase I clinical trials
where a drug is tested for safety
Phase II testing
is the midpoint for a drug's development.
If Phase II is successful, then a drug moves on to:
Phase III
the pivotal stage where a product is tested in a large patient population to determine its effectiveness in treating disease
Trials Available
ASSURE Study
- a study of the possible benefits of Sutent (Sunitinib) manufactured & marketed by Pfizer & Nexavar (Sorafenib) manufactured & marketed by Bayer when used in an adjuvant or neo adjuvent role after surgery.
Sutent / Sunitinib
There would seem to be over 150 Trials & Studies of Sutent - some current, some past and some still recruiting. We have aggregated here those of which we are aware pertaining largely to Urological Cancers - almost 50 as at 25-Jan-2008
Sutent Trial (KC) 01
- Recruiting A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
Sutent Trial (KC) 02
- Recruiting Sunitinib and/or Bevacizumab in Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma
Sutent Trial (PC) 01
- Recruiting Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
Sutent Trial (KC) 03
- Recruiting Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic RCC
Sutent Trial (PC) 02
- Recruiting Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Sutent Trial (KC) 04
Sutent Trial (KC) 05
- Recruiting A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Sutent Trial (KC) 06
- Recruiting Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Sutent Trial (KC) 07
- Not yet recruiting Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Sutent Trial (PC) 03
- Completed Study of SU11248 in Men With Advanced Prostate Cancer
Sutent Trial (KC) 08
- Recruiting A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Sutent Trial (KC) 09
- Suspended A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
Sutent Trial (KC) 10
- Recruiting Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-Risk Patients With Metastatic Renal Cell Carcinoma
Sutent Trial (KC) 11
- Recruiting A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
Sutent Trial (KC) 12
- Recruiting Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
Sutent Trial (KC) 13
- Recruiting Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Sutent Trial (KC) 14
- Recruiting Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
Sutent Trial (KC) 15
- Recruiting Evaluation Study of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
Sutent Trial (KC) 16
- Recruiting Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Sutent Trial (KC) 17
- Recruiting Randomized Phase II Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced RCC
Sutent Trial (BC) 01
- Not yet recruiting SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial
Sutent Trial (KC) 18
- Active, not recruiting SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Sutent Trial (KC) 19
- Enrolling by invitation Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutent
Sutent Trial (KC) 20
- Recruiting A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Placebo In Adjuvant Treatment Of High Risk Renal Cell Cancer
Sutent Trial (BC) 02
Sutent Trial (KC) 21
- Recruiting A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Sutent Trial (KC) 22
- Active, not recruiting SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
Sutent Trial (KC) 23
- Active, not recruiting A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Sutent Trial (KC) 24
- Active, not recruiting Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Sutent Trial (KC) 25
- Recruiting Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
Sutent Trial (KC) 26
- Recruiting Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Sutent Trial (BC) 03
- Recruiting Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
Sutent Trial (KC) 27
- Recruiting Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
Sutent Trial (KC) 28
- Active, not recruiting Study of SU011248 in Patients With Advanced Kidney Cancer
Sutent Trial (KC) 29
- Terminated A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
Sutent Trial (KC) 30
- Recruiting Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery
Sutent Trial (KC) 31
- Not yet recruiting SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Sutent Trial (KC) 32
- Recruiting Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Sutent Trial (KC) 33
- Active, not recruiting Study Of SU011248 Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Sutent Trial (KC) 34
- Recruiting Perifosine + Sunitinib Malate for Patients With Advanced Cancers
Sutent Trial (KC) 35
- Recruiting Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Sutent Trial (BC) 04
- Recruiting Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium TCC & KC
Sutent Trial (KC) 36
- Recruiting Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium TCC & KC
Sutent Trial (KC) 37
- Recruiting Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
Sutent Trial (KC) 38
- Recruiting Sunitinib in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
Sutent Trial (TC) 01
- Recruiting Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
Sutent Trial (KC) 39
- Recruiting Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
Sutent Trial (PC) 04
- Active, not recruiting Phase II Sunitinib Prog Met AIPC
Sutent Trial (KC) 40
- Recruiting Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
Sutent Trial (KC) 41
- Not yet recruiting An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy
Sutent Trial (KC) 42
- Recruiting Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
Sutent Trial (KC) 43
- Not yet recruiting Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Sutent Trial (KC) 44
- Completed Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
Sutent Trial (KC) 45
- Active, not recruiting Everolimus Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
Sutent Trial (KC) 46
- Recruiting Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Sutent Trial (KC) 47
- Recruiting A Ph II Trial of Perifosine Following TKI-Failure in Patients With Renal Cancer
TroVax
TRIST
- A Trovax Renal Immunotherapy Survival Trial of the drug TroVax by Oxford Biomedica
Trovax (KC)
- (Active NOT Recruiting as at 24-Jan-08) Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
Trovax (PC)
- (Completed) Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
Trovax (PC)
- (Recruiting as at 24-Jan-08) Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
Trovax (KC)
- (Recruiting as at 24-Jan-08) TroVax Renal Immunotherapy Survival Trial Clear Cell Renal Carcinoma
Trovax (KC)
- (Active, NOT recruiting as at 24-Jan-08) Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma
Trovax (KC)
- (Recruiting as at 24-Jan-08) A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
References
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
